We are live on ! Find out more

Kiniksa Pharmaceuticals

KNSA

Market cap $7.67B

97.56 USD

+2.38

2.5%

At close Updated Oct 29, 4:00 PM EDT

Pre-market

After hours

97.56

0.00

0%

1 day

2.5%

5 days

21.71%

1 month

28.83%

3 months

20.56%

6 months

84.11%

Year to date

132.23%

1 year

161%

5 years

838.98%

10 years

401.08%

About: Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

Employees: 366

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 46.7%

Neutral 46.7%

Negative 6.7%

The Motley Fool

Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term Investors

Kiniksa raised 2026 revenue guidance to over $1.045 billion. ARCALYST penetration among multiple recurrence patients reached 23%.

Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term Investors

What Kiniksa Pharmaceuticals International (KNSA) Said on Its Q3 Earnings Call

Kiniksa Pharmaceuticals International NASDAQ: KNSA raised its full-year 2026 revenue guidance after reporting third-quarter ARCALYST revenue growth of 58% year over year, as the company continued to expand use of the drug for recurrent pericarditis and advance its clinical pipeline.

What Kiniksa Pharmaceuticals International (KNSA) Said on Its Q3 Earnings Call

Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2026 Earnings Call Transcript

Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2026 Earnings Call Transcript

Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2026 Earnings Call Transcript

Zacks Investment Research

Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings and Revenues Surpass Estimates

Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.23 per share a year ago.

Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings and Revenues Surpass Estimates

Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution

– ARCALYST ® (rilonacept) Q3 2026 net product revenue of $286.0 million, representing ~58% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $1.045 - $1.050 billion – – KPL-387 pivotal Phase 3 data expected in 2H 2027 – – Conference call and webcast scheduled for 8:30 am ET today – LONDON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today reported third quarter 2026 financial results and recent portfolio execution. “Kiniksa continues to build a leading IL-1α and IL-1β inhibition franchise, driven by the commercialization of ARCALYST in recurrent pericarditis.

Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026

LONDON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 27, 2026 at 8:30 a.m. Eastern Time to report its third quarter 2026 financial results and recent portfolio execution.

Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026

Zacks Investment Research

Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why

KNSA is gaining momentum as Arcalyst sales surge and pipeline advances strengthen prospects for continued growth.

Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why

Investors Business Daily

Biopharmaceutical Leader Kiniksa Poised To Hit New Buy Point After Big Revenue Beat

Biotech leader Kiniksa stock is poised to hit a fresh buy point after shares soared 25% in response to better-than-expected sales numbers.

Biopharmaceutical Leader Kiniksa Poised To Hit New Buy Point After Big Revenue Beat

Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference

LONDON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026 at 8:45 a.m. Eastern Time.

Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference

Investors Business Daily

Three Biotech Stocks Stick Out With Their Stellar Charts

These biotech stocks all popped after their recent earnings reports. All three have outperformed 97% of stocks in the last 12 months.

Three Biotech Stocks Stick Out With Their Stellar Charts

See News Rankings

Price charts implemented using Lightweight Charts™